Etoposide trials for Lung cancer

All Etoposide trials · All Lung cancer trials

Phase breakdown

Recruiting trials studying Etoposide for Lung cancer

• A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
  NCT07227597 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 52 locations
• A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer
  NCT07381829 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC
  NCT06177925 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)
  NCT07502300 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
  NCT07005128 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 164 locations
• A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer
  NCT06483282 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of Ivonescimab in First-Line ES-SCLC
  NCT07245446 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 3 locations
• A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer
  NCT07739758 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Study on the Efficacy of Atezolizumab Combined with Chemotherapy
  NCT06780826 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer
  NCT06480864 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).
  NCT06663098 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 25 locations
• Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
  NCT05800587 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
  NCT05068232 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• IN10018 Combination Therapy in Treatment-naïve ES-SCLC
  NCT06030258 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 3 locations
• Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer
  NCT04696575 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer
  NCT05903092 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC
  NCT06497530 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial
  NCT06256237 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation
  NCT06110572 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC
  NCT06769971 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
  NCT06712355 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 225 locations
• Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC
  NCT06217757 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
  NCT07061535 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study
  NCT07583511 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
  NCT05624996 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 477 locations
• Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC
  NCT06536868 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 6 locations
• Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
  NCT06769126 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 148 locations

Common questions

How many trials study Etoposide for Lung cancer?

27 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.